JP6633609B2 - 肝疾患および他の医学的障害の処置のためのカルボキシ−シクロプロピルウンデカノール化合物 - Google Patents

肝疾患および他の医学的障害の処置のためのカルボキシ−シクロプロピルウンデカノール化合物 Download PDF

Info

Publication number
JP6633609B2
JP6633609B2 JP2017501126A JP2017501126A JP6633609B2 JP 6633609 B2 JP6633609 B2 JP 6633609B2 JP 2017501126 A JP2017501126 A JP 2017501126A JP 2017501126 A JP2017501126 A JP 2017501126A JP 6633609 B2 JP6633609 B2 JP 6633609B2
Authority
JP
Japan
Prior art keywords
carboxy
medicament
liver
medicament according
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017501126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509701A5 (https=
JP2017509701A (ja
Inventor
ジェフリー・シー・ハンゼルマン
ライ・アジト・ケイ・スリバスタバ
ロジャー・エス・ニュートン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esperion Therapeutics Inc
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of JP2017509701A publication Critical patent/JP2017509701A/ja
Publication of JP2017509701A5 publication Critical patent/JP2017509701A5/ja
Application granted granted Critical
Publication of JP6633609B2 publication Critical patent/JP6633609B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017501126A 2014-03-20 2015-03-20 肝疾患および他の医学的障害の処置のためのカルボキシ−シクロプロピルウンデカノール化合物 Expired - Fee Related JP6633609B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461968082P 2014-03-20 2014-03-20
US61/968,082 2014-03-20
PCT/US2015/021677 WO2015143276A1 (en) 2014-03-20 2015-03-20 Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders

Publications (3)

Publication Number Publication Date
JP2017509701A JP2017509701A (ja) 2017-04-06
JP2017509701A5 JP2017509701A5 (https=) 2018-04-26
JP6633609B2 true JP6633609B2 (ja) 2020-01-22

Family

ID=54145365

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017501126A Expired - Fee Related JP6633609B2 (ja) 2014-03-20 2015-03-20 肝疾患および他の医学的障害の処置のためのカルボキシ−シクロプロピルウンデカノール化合物

Country Status (6)

Country Link
US (1) US20170209402A1 (https=)
EP (1) EP3119388B1 (https=)
JP (1) JP6633609B2 (https=)
AU (1) AU2015231076B2 (https=)
CA (1) CA2942100A1 (https=)
WO (1) WO2015143276A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1257929A1 (zh) * 2015-11-06 2019-11-01 Gemphire Therapeutics Inc. 治疗混合性血脂异常
WO2019179494A1 (zh) * 2018-03-23 2019-09-26 深圳市塔吉瑞生物医药有限公司 取代的十五烷二酸化合物及药物组合物及其用途
CN112675159A (zh) * 2021-01-12 2021-04-20 杭州师范大学 L-苹果酸在制备防治肝脏缺血再灌注损伤药物中的应用
WO2024212248A1 (en) * 2023-04-14 2024-10-17 Meta Pharmaceuticals (Hk) Limited Substituted alkanoic-diacids compound and composition and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2625429T3 (es) * 2003-01-23 2017-07-19 Esperion Therapeutics Inc. Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes
JP2013537240A (ja) * 2010-09-20 2013-09-30 カリウス セラピューティクス エスエー 糖尿病および脂質異常症の処置のための方法および組成物

Also Published As

Publication number Publication date
EP3119388A4 (en) 2017-11-22
AU2015231076A1 (en) 2016-09-22
WO2015143276A1 (en) 2015-09-24
AU2015231076B2 (en) 2020-05-21
EP3119388A1 (en) 2017-01-25
US20170209402A1 (en) 2017-07-27
JP2017509701A (ja) 2017-04-06
EP3119388B1 (en) 2020-06-17
CA2942100A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
US20220152022A1 (en) Methods for increasing growth in pediatric subjects having cholestatic liver disease
US8642661B2 (en) Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists
EP3411026B1 (en) Use of stimulators of soluble guanylate cyclase for the treatment of nonalcoholic steatohepatitis (nash)
US12595481B2 (en) Methods and compositions for neuroprotection
JP6633609B2 (ja) 肝疾患および他の医学的障害の処置のためのカルボキシ−シクロプロピルウンデカノール化合物
JP2022145949A (ja) 特定の患者集団において神経変性障害を処置する方法
AU2016342375A1 (en) Analogs of celastrol
WO2014124396A1 (en) Therapeutic strategies for the treatment of preeclampsia
TW202337456A (zh) Ｇｍ２神經節苷脂症之治療
JP2025118759A (ja) 血管型エーラース・ダンロス症候群および関連障害を処置するための組成物および方法
TW202333723A (zh) 頂端鈉依賴型膽酸轉運蛋白抑制劑(asbti)之給藥方法
CN109476686B (zh) sGC刺激剂的磷前药
CN107427480A (zh) 用于预防和/或治疗脂肪性肝炎的脂肪酸酰胺
CA3159374C (en) Methods and compositions for neuroprotection
US20240180891A1 (en) Synergistic modulators of alpha-dicarbonyl detoxification and their use for inducing weight loss and the treatment of diabetic pathologies
JP2026507218A (ja) ３，４，５－三置換トリアゾールの調製およびその使用方法
WO2022265984A1 (en) Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders
HK40129994A (zh) 患有胆汁盐输出泵缺乏症的患者对asbti的基因型和剂量依赖性应答
HK40065058A (en) Methods for increasing growth in pediatric subjects having cholestatic liver disease
HK40065058B (en) Methods for increasing growth in pediatric subjects having cholestatic liver disease
JP2023536590A (ja) 精神障害性疾患を予防および治療するための化合物およびその適用
JP2009057303A (ja) 中枢性排尿障害の治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191212

R150 Certificate of patent or registration of utility model

Ref document number: 6633609

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees